Join Growin Stock Community!

Indivior pharmaceuticals incINDV.US Overview

US StockHealthcare
(No presentation for INDV)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

INDV AI Insights

INDV Overall Performance

INDV AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

INDV Recent Performance

-3.25%

Indivior pharmaceuticals inc

0.05%

Avg of Sector

-0.31%

S&P500

INDV PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

INDV Key Information

INDV Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

INDV Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Price of INDV

INDV FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

INDV Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.68
PE Ratio (TTM)
33.39
Forward PE
23.51
PS Ratio (TTM)
3.30
PB Ratio
145.25
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
80.16%
Net Margin
16.85%
Revenue Growth (YoY)
4.29%
Profit Growth (YoY)
3.76%
3-Year Revenue Growth
12.79%
3-Year Profit Growth
13.11%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.68
PE Ratio (TTM)
33.39
Forward PE
23.51
PS Ratio (TTM)
3.30
PB Ratio
145.25
Price-to-FCF
-
Gross Margin
80.16%
Net Margin
16.85%
Revenue Growth (YoY)
4.29%
Profit Growth (YoY)
3.76%
3-Year Revenue Growth
12.79%
3-Year Profit Growth
13.11%

  • When is INDV's latest earnings report released?

    The most recent financial report for Indivior pharmaceuticals inc (INDV) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating INDV's short-term business performance and financial health. For the latest updates on INDV's earnings releases, visit this page regularly.

  • Where does INDV fall in the P/E River chart?

    According to historical valuation range analysis, Indivior pharmaceuticals inc (INDV)'s current price-to-earnings (P/E) ratio is 20.08, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of INDV?

    According to the latest financial report, Indivior pharmaceuticals inc (INDV) reported an Operating Profit of 81M with an Operating Margin of 22.63% this period, representing a decline of 15.63% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is INDV's revenue growth?

    In the latest financial report, Indivior pharmaceuticals inc (INDV) announced revenue of 358M, with a Year-Over-Year growth rate of 19.73%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does INDV have?

    As of the end of the reporting period, Indivior pharmaceuticals inc (INDV) had total debt of 351M, with a debt ratio of 0.29. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does INDV have?

    At the end of the period, Indivior pharmaceuticals inc (INDV) held Total Cash and Cash Equivalents of 195M, accounting for 0.16 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does INDV go with three margins increasing?

    In the latest report, Indivior pharmaceuticals inc (INDV) achieved the “three margins increasing” benchmark, with a gross margin of 81.3%%, operating margin of 22.63%%, and net margin of 28.5%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess INDV's profit trajectory and future growth potential.

  • Is INDV's EPS continuing to grow?

    According to the past four quarterly reports, Indivior pharmaceuticals inc (INDV)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.81. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of INDV?

    Indivior pharmaceuticals inc (INDV)'s Free Cash Flow (FCF) for the period is -245M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 231.08% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of INDV?

    The latest valuation data shows Indivior pharmaceuticals inc (INDV) has a Price-To-Earnings (PE) ratio of 20.08 and a Price/Earnings-To-Growth (PEG) ratio of 0.08. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.